Gemtuzumab ozogamicin

Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). The antibody portion is Gemtuzumab (HY-P99971), and the drug-linker conjugate for ADC is N-Ac-γ-Calicheamicin-AcBut-NHS ester (HY-103688). Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML)^[1][2]. In Vitro:Gemtuzumab ozogamicin (1-250 ng/mL ; 72 hours) has cell cytotoxicity in CD33-positive cells^[1].
Gemtuzumab ozogamicin is an ADC. After binding of the antibody to CD33 and subsequent internalization, Calicheamicin mediates cytotoxicity to CD33-positive myeloid cells primarily through induction of DNA damage and subsequent apoptosis^[1].
Gemtuzumab ozogamicin iproduces significant inhibition of colony formation in cultures of adult leukemic bone marrow cells^[3].
Gemtuzumab ozogamicin (5-100 μg/L) suppressed the cell growth of HL-60, NOMO-1, NB-3 and NKM-1 cell lines in a dose-dependent manner^[3].
Gemtuzumab ozogamicin (Compound GO) (1-100 nM, 24 h) induces dose-dependent capase activation at 10 and 100 nM in HL-60 cells^[4].
Gemtuzumab ozogamicin (1 nM-1 μM, 72 h) kills 95.05% of HL-60 and 42.61% of K-562 cells^[4].